Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis
World Journal of Cardiology · 26.07.2026 · 18 (7)
DOI: 10.4330/wjc.121611 ↗Kurz gefasst
Metaanalyse in der Zeitschrift World Journal of Cardiology, online erschienen am 26.07.2026. Verfasst von Vyom Patel und 9 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III (apoC-III), has shown promise in reducing triglyceride (TG) levels in patients with high-risk hypertriglyceridemia. This meta-analysis evaluates the comparative efficacy of different dosing regimens. AIM To compare the efficacy and safety of olezarsen 80 mg vs 50 mg in patients with high-risk hypertriglyceridemia through a systematic review and meta-analysis of randomized controlled trials (RCTs). METHODS PubMed, the Cochrane Library, and Google Scholar were searched for RCTs comparing olezarsen 80 mg to 50 mg. Three studies were analyzed using RevMan 5.4.1 random-effects models to obtain mean difference (MD) with 95%CIs. RESULTS Olezarsen 80 mg showed statistically significant reduction in apoC-III (MD = -0.26; 95%CI: -0.51 to - 0.01; P = 0.04). Whereas no difference was seen in TG levels (MD = -0.72; 95%CI: -1.55 to 0.12; P = 0.09), low density lipoproteins (MD = -0.03; 95%CI: -0.16 to 0.10, P = 0.67), very low-density lipoproteins (MD = -0.09; 95%CI: -0.22 to 0.04; P = 0.18), non-high-density lipoproteins (HDL; MD = -0.16; 95%CI: -0.50 to 0.18, P = 0.35), HDL (MD = 0.05; 95%CI: -0.08 to 0.18; P = 0.44), apolipoprotein B (MD = -0.91; 95%CI: -2.70 to 0.88; P = 0.32), adverse effects [AEs; relative risk (RR) = 1.04; 95%CI: 0.96-1.11; P = 0.35], serious AE (RR = 1.40; 95%CI: 0.97-2.02; P = 0.07), hypersensitivity reaction (RR = 1.71; 95%CI: 0.51-5.75; P = 0.39), renal dysfunction (RR = 1.13; 95%CI: 0.62-2.04; P = 0.69), hepatic dysfunction (RR = 1.07, 95%CI: 0.55-2.09; P = 0.84) or thrombocytopenia (RR = 1.57; 95%CI: 0.28-8.75; P = 0.61). CONCLUSION Apart from a limited dose-dependent effect on apoC-III, higher dose is not associated with any definitive advantage or disadvantage, highlighting a need for further research.
Zitieren
APA
Patel, V., Sohail, R., Alam, M., Chaudhry, S., Mehdi, S., Patel, S., Patel, R., Khattak, R., Khan, Z., & Patel, M. (2026). Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World Journal of Cardiology, 18(7). https://doi.org/10.4330/wjc.121611
Vancouver
Patel V, Sohail R, Alam M, Chaudhry S, Mehdi S, Patel S, et al. Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis. World Journal of Cardiology. 2026;18(7). doi:10.4330/wjc.121611
BibTeX
@article{Patel2026,
author = {Patel, Vyom and Sohail, Rohab and Alam, Madihah and Chaudhry, Shahryar and Mehdi, Samar and Patel, Simran and Patel, Rohan and Khattak, Ridda and Khan, Zaraq and Patel, Manan},
title = {Dose-dependent efficacy of olezarsen in high-risk hypertriglyceridemia: A meta-analysis},
journal = {World Journal of Cardiology},
year = {2026},
volume = {18},
number = {7},
doi = {10.4330/wjc.121611}
}
EUVIMED